NEW YORK (GenomeWeb News) – Thomson Reuters today said it and Orion Bionetworks are collaborating to elucidate the biological underpinnings of multiple sclerosis.

The collaboration also seeks to develop new therapies by generating predictive models of patient stratification and drug targets. Together, Thomson Reuters and Orion will combine their expertise and assets to "integrate and interpret clinical, molecular, imaging, and real-world patient data to develop new predictive models for" MS, Thomson Reuters said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."